Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MURCIDENCEL dendritic cell IL-12 vaccine in high-risk paediatric solid tumours
2024-516613-21-00Phase 2Completed
- Sponsor
- Masaryk University
- Start
- Nov 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of murcidencel in childhood solid tumors, sponsored by Masaryk University. Primary endpoint: Combined primary endpoint of safety. Started Nov 2024; status: completed.
02
Drugs
murcidencel
03
Conditions
childhood solid tumors
Beyond the preview
Go deeper on 2024-516613-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516613-21-00.